Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd

Bullboard Posts

Post by GoldMan22on Dec 25, 2010 1:14pm

411 Views

Post# 17895195

Pinetree loading up with NOX

https://canadianinsider.com/coReport/allTransactions.php?ticker=nox

Niogold Mining Corp. (NOX)						As of December 24th, 2010
Filing Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	# or value acquired or disposed of	Unit Price
Dec 24/10	Dec 23/10	Pinetree Capital Ltd.	Indirect Ownership	Warrants	11 - Acquisition carried out privately	750,000	.480
Dec 24/10	Dec 23/10	Pinetree Capital Ltd.	Indirect Ownership	Common Shares	11 - Acquisition carried out privately	1,500,000	.320
Dec 23/10	Dec 23/10	Iverson, Michael Alexander	Direct Ownership	Common Shares	16 - Acquisition under a prospectus exemption	100,000	.320